Stock comparison
IDEXX Laboratories
Stryker
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.06B
Sector
Healthcare
SYK
Stryker
Market cap
$121.8B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | SYK | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 65B | IDXX |
| Benjamin Graham | 80A | 83A | SYK |
| Philip Fisher | 75B | 67C | IDXX |
| Peter Lynch | 71B | 68B | IDXX |
| Joel Greenblatt | 83C | 50D | IDXX |
| Charlie Munger | 87A | 63D | IDXX |
| Terry Smith | 84A | 62D | IDXX |
Side-by-side metrics
| Metric | IDXX | SYK |
|---|---|---|
| Market cap | $44.06B | $121.8B |
| P/E (TTM) | 39.0x | 35.2x |
| EV/EBIT | 31.6x | 26.4x |
| ROIC (TTM) | 40.66% | 9.79% |
| Gross margin | 62.05% | 63.67% |
| Net margin | 24.63% | 13.21% |
| Revenue CAGR 5y | 7.56% | 10.07% |
| EPS CAGR 5y | 10.79% | 12.55% |
| Debt / Equity | 0.7x | 0.6x |
| Dividend yield | 0.0% | 1.12% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- ROIC (TTM)40.66%vs 9.79%+76%
- Net margin24.63%vs 13.21%+46%
SYK leads on
- Dividend yield1.12%vs 0.0%+100%
- Market cap$121.8Bvs $44.06B+64%
- Revenue CAGR 5y10.07%vs 7.56%+25%
- EV/EBIT26.4xvs 31.6x+17%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.